Market Runner: Novartis AG (ADR) Has Another Very Weak Trading Session

Market Runner: Novartis AG (ADR) Has Another Very Weak Trading Session

The stock of Novartis AG (ADR) (NYSE:NVS) is a huge mover today! About 1.14M shares traded hands. Novartis AG (ADR) (NYSE:NVS) has risen 4.09% since March 10, 2016 and is uptrending. It has underperformed by 3.43% the S&P500.
The move comes after 7 months negative chart setup for the $195.07 billion company. It was reported on Oct, 13 by Barchart.com. We have $70.02 PT which if reached, will make NYSE:NVS worth $13.65B less.

Analysts await Novartis AG (ADR) (NYSE:NVS) to report earnings on October, 25. They expect $1.19 EPS, down 6.30% or $0.08 from last year’s $1.27 per share. NVS’s profit will be $3.08 billion for 15.82 P/E if the $1.19 EPS becomes a reality. After $1.22 actual EPS reported by Novartis AG (ADR) for the previous quarter, Wall Street now forecasts -2.46% negative EPS growth.

Novartis AG (ADR) (NYSE:NVS) Ratings Coverage

Out of 9 analysts covering Novartis Ag (NYSE:NVS), 2 rate it a “Buy”, 2 “Sell”, while 5 “Hold”. This means 22% are positive. Novartis Ag has been the topic of 13 analyst reports since July 28, 2015 according to StockzIntelligence Inc. On Tuesday, April 5 the stock rating was initiated by Argus Research with “Hold”. On Tuesday, September 20 the stock rating was initiated by Chardan Capital Markets with “Buy”. The firm has “Neutral” rating by Citigroup given on Tuesday, March 29. The rating was downgraded by Mainfirst on Wednesday, October 28 to “Underperform”. The firm has “Market Perform” rating given on Wednesday, March 23 by Leerink Swann. As per Friday, April 1, the company rating was downgraded by UBS. Chardan Capital Markets maintained the stock with “Buy” rating in Monday, October 10 report. The rating was downgraded by Morgan Stanley on Tuesday, April 12 to “Underperform”.

According to Zacks Investment Research, “Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.”

NVS Company Profile

Novartis AG, incorporated on March 1, 1996, is a holding company. The Firm specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s divisions include Pharmaceuticals, which researches, develops, makes, distributes and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines; Alcon, which operates through over three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, makes and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment